Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Phase 3 Trial; Shares Fall Pre-Bell

MT Newswires Live

Jul 31

Novo Nordisk (NVO) said Friday its drug candidate, ziltivekimab, did not reduce major adverse cardiovascular events in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation compared with a placebo in a phase 3 trial.

The trial evaluated once-monthly ziltivekimab 15 mg compared with placebo for rreducing the risk of major adverse cardiovascular events, or MACE, which are defined as cardiovascular death, non-fatal heart attack or non-fatal stroke.

The company said two additional ongoing cardiovascular outcome trials evaluating the drug candidate in people with heart failure an in people following an acute heart attack will continue and are expected to read out their results in H1 2027.

Shares of Novo Nordisk fell more than 10% in recent premarket activity Friday.

Price: 46.26, Change: -5.35, Percent Change: -10.37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2655365671"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2655365671\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2655365671?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 19:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655365671","market":"us","top_or_hot":-1,"title":"Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Phase 3 Trial; Shares Fall Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) said Friday its drug candidate, ziltivekimab, did not reduce major adverse cardiovascular events in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation compared with a placebo in a phase 3 trial.</p><p>The trial evaluated once-monthly ziltivekimab 15 mg compared with placebo for rreducing the risk of major adverse cardiovascular events, or MACE, which are defined as cardiovascular death, non-fatal heart attack or non-fatal stroke.</p><p>The company said two additional ongoing cardiovascular outcome trials evaluating the drug candidate in people with heart failure an in people following an acute heart attack will continue and are expected to read out their results in H1 2027.</p><p>Shares of Novo Nordisk fell more than 10% in recent premarket activity Friday.</p><p>Price: 46.26, Change: -5.35, Percent Change: -10.37</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Phase 3 Trial; Shares Fall Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Phase 3 Trial; Shares Fall Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-31 19:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) said Friday its drug candidate, ziltivekimab, did not reduce major adverse cardiovascular events in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation compared with a placebo in a phase 3 trial.</p><p>The trial evaluated once-monthly ziltivekimab 15 mg compared with placebo for rreducing the risk of major adverse cardiovascular events, or MACE, which are defined as cardiovascular death, non-fatal heart attack or non-fatal stroke.</p><p>The company said two additional ongoing cardiovascular outcome trials evaluating the drug candidate in people with heart failure an in people following an acute heart attack will continue and are expected to read out their results in H1 2027.</p><p>Shares of Novo Nordisk fell more than 10% in recent premarket activity Friday.</p><p>Price: 46.26, Change: -5.35, Percent Change: -10.37</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2655365671","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655365671","pubTimestamp":1785498661,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  said Friday its drug candidate, ziltivekimab, did not reduce major adverse cardiovascular events in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation compared with a placebo in a phase 3 trial.The trial evaluated once-monthly ziltivekimab 15 mg compared with placebo for rreducing the risk of major adverse cardiovascular events, or MACE, which are defined as cardiovascular death, non-fatal heart attack or non-fatal stroke.The company said two additional ongoing cardiovascular outcome trials evaluating the drug candidate in people with heart failure an in people following an acute heart attack will continue and are expected to read out their results in H1 2027.Shares of Novo Nordisk fell more than 10% in recent premarket activity Friday.Price: 46.26, Change: -5.35, Percent Change: -10.37","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4007":"制药","PPH":"VanEck Pharmaceutical ETF","OZEM":"Roundhill GLP-1 & Weight Loss ETF","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","BK4599":"减肥药","NVOH":"Novo Nordisk A/S B Shares ADRhedged","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","NVOX":"2倍做多NVO ETF-Defiance","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓"},"translate_title":"诺和诺德称Ziltivekimab未能在3期试验中减少主要不良心血管事件；盘前股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.97,"NVOH":0.6,"THNR":0.6,"OZEM":0.6,"NVOX":0.6,"PPH":0.6},"content_text":"Novo Nordisk (NVO) said Friday its drug candidate, ziltivekimab, did not reduce major adverse cardiovascular events in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation compared with a placebo in a phase 3 trial.The trial evaluated once-monthly ziltivekimab 15 mg compared with placebo for rreducing the risk of major adverse cardiovascular events, or MACE, which are defined as cardiovascular death, non-fatal heart attack or non-fatal stroke.The company said two additional ongoing cardiovascular outcome trials evaluating the drug candidate in people with heart failure an in people following an acute heart attack will continue and are expected to read out their results in H1 2027.Shares of Novo Nordisk fell more than 10% in recent premarket activity Friday.Price: 46.26, Change: -5.35, Percent Change: -10.37","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}